Why the study?
Does routine use of glycoprotein IIb/IIIa antagonists prevent stent thrombosis in morphine-treated STEMI patients undergoing PPCI?
Does routine use of glycoprotein IIb/IIIa antagonists prevent stent thrombosis in morphine-treated STEMI patients undergoing PPCI?
Routine use of glycoprotein IIb/IIIa antagonists may protect against stent thrombosis in morphine-treated STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
Supports routine GPI consideration in morphine-treated STEMI patients undergoing PPCI; extends evidence for targeted antiplatelet strategies in this subgroup.
= .002). In conclusion, routine GPI use in morphine-treated STEMI patients undergoing PPCI appears to protect against stent thrombosis. Large-scale studies are needed to establish the overall risk-benefit of GPI therapy in morphine-treated PPCI patients and to assess alternative strategies for preventing acute stent thrombosis in these patients.
No takes yet. Share an insight, caveat, or question.
Zwart et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: